Engineering Conferences International

ECI Digital Archives
Vaccine Technology VIII

Proceedings

6-12-2022

On-Line influenza virus quantification for viral production
processes thanks to affinity-based surface plasmon resonance
biosensor
Emma Petiot
ICBMS-Gembas Laboratory, France

Laurent Durous
Univ Lyon, Université Lyon1, CNRS, INSA, CPE-Lyon, France

Manuel Rosa-Calatrava
Univ Lyon, VirPath Team, Inserm U1111, CNRS UMR5308, France

Christophe A. Marquette
Univ Lyon, Université Lyon1, CNRS, INSA, CPE-Lyon, France

Follow this and additional works at: https://dc.engconfintl.org/vaccine_viii

Recommended Citation
Emma Petiot, Laurent Durous, Manuel Rosa-Calatrava, and Christophe A. Marquette, "On-Line influenza
virus quantification for viral production processes thanks to affinity-based surface plasmon resonance
biosensor" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles
Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia,
Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/
vaccine_viii/30

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been
accepted for inclusion in Vaccine Technology VIII by an authorized administrator of ECI Digital Archives. For more
information, please contact franco@bepress.com.

ON-LINE INFLUENZA VIRUS QUANTIFICATION FOR APPLICATION TO VIRAL PRODUCTION
PROCESSES THANKS TO AFFINITY-BASED SURFACE PLASMON RESONANCE BIOSENSOR
Emma PETIOT, PhD, Univ Lyon, Université Lyon1, CNRS, INSA, CPE-Lyon, ICBMS, France
emma.petiot@univ-lyon1.fr
Laurent DUROUS, PhD, Univ Lyon, Université Lyon1, CNRS, INSA, CPE-Lyon, France
Manuel ROSA-CALATRAVA, PhD, Univ Lyon, VirPath Team, Inserm U1111, CNRS UMR5308
Christophe A. MARQUETTE, PhD, Univ Lyon, Université Lyon1, CNRS, INSA, CPE-Lyon, France

Key Words: Influenza virus, Cell culture, Surface plasmon resonance (SPR), Potency assay, Process analytical
technology (PAT)
Influenza virus seasonal epidemics, associated with the constant threat of new pandemic outbreak, challenge
vaccine manufacturers to develop responsive processes that can outreach the limitations of traditional eggbased technology. Recent progress made regarding cell culture bioprocesses allowed for numerous alternative
strategies to developed future vaccine candidates, as for example the recombinant HA or Virus—like Particles
(VLP) vaccines. However, while cell culture allows for more versatility than ovoculture, regarding process
development and monitoring, these alternatives still require optimization to seriously concurrence the traditional
process. To drive these developments, WHO and regulatory agencies underlined the need for developing better
influenza vaccine potency assays 1,2. Actual influenza vaccine formulation and lot release rely on single-radial
immunodiffusion (SRID) assay, which requires strain-specific reference sera and antigen reagents. However,
the annual preparation of these reagents takes between 2 to 6 months and constitutes a critical bottleneck for
the release of vaccine lots3. Additionally, SRID is not implementable for process development as such technique
cannot handle in-process low concentrated and non-purified material. We developed an assay for rapid and
label-free quantification of influenza hemagglutinin (HA) antigen and influenza virus based on surface plasmon
resonance (SPR). The method is based on affinity capture of hemagglutinin antigen by sialic-acid terminated
glycans present at the surface of the fetuin-functionalized sensor. Conditions were optimized for the
regeneration of the surface, in order to run multiple sequential analyses on a unique sensor. Two types of
purified standard were used during the development of the assay. Commercial trivalent inactivated vaccine
(“TIV”) has been used for the determination of optimal analytical conditions, while a stock of split inactivated
H1N1 virus has been produced and calibrated in our laboratory to study the specific response obtained toward
this HA subtype. This assay offers a quantification of influenza hemagglutinin within minutes with a wide
dynamic range (30 ng/mL-20 µg/mL). Also, the technique provides a limit of detection (LOD) 100 times lower
than SRID, and a better reproducibility than SRID and its potential alternatives recently proposed (<5% RSD vs
6-15%)1,4,5. Additionally, the applicability of this assay for an on-line vaccine production monitoring has been
validated by off-line measurement of influenza H1N1 virus particles derived from cell culture supernatant. Such
a test allowed to achieve a LOD of 106 Infectious Viral Particles/mL Thus, our assay provides an innovative tool
to evaluate influenza new vaccine bioprocesses, from viral production kinetics in mammalian cell culture to
vaccine potency evaluation.
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